Multidisciplinary Search
Multidisciplinary Multidisciplinary
Most Read Articles
Physical activity does not increase risk of urological cancer
Yesterday
No association exists between physical activity and the risk of urological cancer, according to a population-based prospective study in Japan.
Olanzapine improves weight in adult outpatients with anorexia nervosa
6 days ago
Olanzapine confers a modest therapeutic effect on weight compared with placebo in adult outpatients with anorexia nervosa, a study has shown. However, it does not appear to offer significant benefit for psychological symptoms.
Childhood-onset inflammatory bowel diseases increase mortality risk
2 days ago
Patients with childhood-onset inflammatory bowel disease are more likely to die than the general population, a study suggests.
Caloric restriction improves glucose metabolism, body-fat composition
2 days ago
Reduced caloric intake results in a significant improvement in glucose metabolism and body-fat composition, including liver-fat content, according to a study. Changes in ferritin levels appear to mediate the striking reduction in liver fat.

Original New Drug Application Approvals by US FDA (16 - 31 January 2019)

31 Jan 2019
New drug applications approved by US FDA as of 16 - 31 January 2019 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

ONTRUZANT
  • Active Ingredient(s): Trastuzumab-dttb
  • Strength: 150 MG
  • Dosage Form(s) / Route(s): Injectable; Injection
  • Company: Samsung Bioepis Co Ltd
  • Approval Date: 18 Jan 2019
  • Submission Classification: Not available
  • Indication(s): Indicated for:
    • The treatment of HER2-overexpressing breast cancer.
    • The treatment of HER2-overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma.
  • Approved Label: 18 Jan 2019 (PDF)
TOSYMRA
  • Active Ingredient(s): Sumatriptan
  • Strength: 10 MG
  • Dosage Form(s) / Route(s): Spray; Nasal
  • Company: Dr Reddy's Labs Ltd
  • Approval Date: 25 Jan 2019
  • Submission Classification:  Type 3 - New Dosage Form
  • Indication(s): Indicated for the acute treatment of migraine with or without aura in adults.
  • Approved Label: 25 Jan 2019 (PDF)
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Physical activity does not increase risk of urological cancer
Yesterday
No association exists between physical activity and the risk of urological cancer, according to a population-based prospective study in Japan.
Olanzapine improves weight in adult outpatients with anorexia nervosa
6 days ago
Olanzapine confers a modest therapeutic effect on weight compared with placebo in adult outpatients with anorexia nervosa, a study has shown. However, it does not appear to offer significant benefit for psychological symptoms.
Childhood-onset inflammatory bowel diseases increase mortality risk
2 days ago
Patients with childhood-onset inflammatory bowel disease are more likely to die than the general population, a study suggests.
Caloric restriction improves glucose metabolism, body-fat composition
2 days ago
Reduced caloric intake results in a significant improvement in glucose metabolism and body-fat composition, including liver-fat content, according to a study. Changes in ferritin levels appear to mediate the striking reduction in liver fat.